English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The general pharmacological studies of VP 16-213, an antitumor agent, in the peripheral system were carried out by oral and i.v. administration with laboratory animals. VP 16-213 had no effect on the resting tone and spontaneous motility of all the isolated smooth muscle organs tested at concentrations of up to 10(-5) g/ml. VP 16-213 showed no significant influences on the neuromuscular transmission in the sciatic nerve-tibial muscle preparation of rabbits, on renal function in dogs and rats, on blood sugar level in rabbits, and on charcoal meal transport in mice. At a dose of 20 mg/kg, i.v., VP 16-213 reduced gastric secretion in rats. Antiinflammatory, local irritation and hemolytic effects were not observed after the administration of the drug. Single administration of VP 16-213 had orally no effect on the excretion of serum BSP in rats. However, successive administration of the drug (20 mg/kg/day) once daily for 10 days significantly depressed it. VP 16-213 decreased the number of hemolytic plaque forming cells in the spleens of immunized mice.

General pharmacological studies of VP 16-213. Effect on the peripheral system.